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The 5 year survival rate for patients with metastatic non-
seminomatous germ cell tumours is now over 80% with first line
chemotherapy (International Germ Cell Cancer Collaboration
Group, 1997). Treatment includes orchidectomy and platinum-
based combination chemotherapy. Residual masses, particularly in
the retroperitoneum, may remain after chemotherapy. Since the
early surgical resections by Einhorn et al (1981), it has become
almost routine to perform retroperitoneal lymph node dissections
(RPLND) in these patients (Ravi et al, 1997). Histology from these
masses has a wide spectrum of appearances including necrosis,
teratoma, mature (TM), or malignant elements – embryonal carci-
noma (EC) or teratoma, immature (TI). The percentage of each in
one study being 45% necrosis, 42% TM and 13% malignant
tumour (Steyerberg et al, 1995). These chemotherapy-treated germ
cell tumours are notoriously difficult for histopathologists to
analyse, when the differentiation between undifferentiated, carci-
nomatous, and dysplastic elements may be extremely contentious. 
Few publications have considered the outcome and manage-
ment of this small group of patients with viable malignant or
immature tumour in RPLNDs. Because of this, the benefit of post-
operative chemotherapy in these patients is controversial. The
relapse rate in patients not treated with further chemotherapy from
our own centre and other studies (Williams et al 1987; Tait et al
1994; Pizzocaro et al, 1998) suggests that many patients are cured
by RPLND alone. It is clear that effective salvage therapy does
exist for those who relapse (Loehrer et al, 1998; Shamash et al,
1999). The two alternative approaches of dealing with these
patients (offer chemotherapy to everyone with residual malignant
elements or only treat those who subsequently relapse) therefore
overtreats or undertreats these patients. 
The current policy at this centre is to offer observation initially
and only offer therapy on subsequent relapse. The purpose of this
study was to investigate the possibility that histological examina-
tion of the viable malignant elements and assessment of the prolif-
eration rate could quantify the risk of relapse and thus allow for
better patient selection in deciding who should have immediate
treatment and for whom watchful waiting was more appropriate. 
MATERIALS AND METHODS 
118 retroperitoneal lymph node dissections were identified from
Barts and The London NHS Trust medical oncology database.
Haematoxylin and eosin-stained slides for each case were
reviewed by a consultant histopathologist, who was blinded to the
outcome of the patient. Where original histopathology slides were
not available, fresh sections were cut and stained and where neces-
sary further immunochemistry performed to determine the diag-
nosis. The cases with malignant, immature or dysplastic elements
were identified, and an assessment of the proportion of the major
tissue elements was made on each case and a percentage assigned
to each tissue type. This was assessed as an overall impression
similar to other studies (Heidenreich et al, 1998). A paraffin block
containing the malignant or immature elements was selected and
used for immunohistochemical staining. 30 out of the total 118
RPLNDs had residual malignant or immature elements. Cases
which had adjuvant chemotherapy before relapse were excluded
so that the natural history of the disease could be determined.
Cases where insufficient tissue remained or the blocks were
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unavailable were also excluded. This left a total of 28 cases with
residual malignant or undifferentiated elements (Table 1). 
Formalin-fixed, paraffin-embedded 3 mm tissue sections were
cut and mounted onto coated slides. Antigen retrieval by pressure
cooking was used. Immunohistochemistry was performed using
the ABC method for Ki-67 with the polyclonal antibody, code
A047 (DAKO). A normal tonsil was used for a positive control. A
negative control was performed for each case. Sections were
counter-stained with Gill’s haematoxylin. Ki-67 was scored as the
number of positive cells out of 500 expressed as a percentage. 500
cells were counted in 10 random fields within the tumour area.
Where less than 500 cells were present within a case, at least 100
cells were counted. No malignant focus included contained less
than 100 cells. Patients were categorized into two groups, those
that relapsed after surgery and those that remain progression free
(non-relapse). 
Statistical analysis was performed using JMP statistics
programme, to determine significant risk factors for relapse.
ShapiroWilk W test found the data unlikely to be from a normal
distribution and so non-parametric Wilcoxon/Kruskal-Wallis Tests
were applied. 
RESULTS 
28 patients were included of whom 12 subsequently relapsed after
RPLND. The mean age of the patients was 32.6. The median
length of follow up of patients that remained progression free is
9.5 years, the minimum follow-up is 36 months. Of patients that
relapsed, the median time after surgery to relapse is 1 month, and
all others relapsed within 11 months except for 1 patient who
relapsed after 30 months. 
Histology 
Embryonal carcinoma (EC) was present in 11/12 of masses from
relapsing patients and 7 out of 14 progression-free patients. There
was a highly significant difference between the percentage of EC
between the two groups (P < 0.0006). No difference was found
between the percentage of yolk sac (YS), TM and necrosis within
each group. TI showed a trend to be more common in the non-
relapse group but this failed to reach significance (P = 0.08). 
Using a cut-off point of >25% EC, 10/11 patients (90.9%)
would have been correctly predicted to relapse after surgery. Using
this test alone to predict the need for further chemotherapy gives a
sensitivity of 75% (9/12), specificity of 93.7% (15/16) and a nega-
tive predictive value of 83.3% (15/18). 
Proliferation index 
16/28 (57.1%) of cases had a Ki-67 index greater than 25%. There
was a significant difference between the proliferation index in the
relapse and non-relapse groups (P < 0.03). A cut-off value of
greater than 50% would have correctly predicted 71.4% (5/7)
patients that relapsed. The sensitivity was 45.5% (5/11), the speci-
ficity was 88.2% (15/17) and the negative predictive value was
71.4% (15/21). 
Table 1 Retroperitoneal lymph node dissections showing different elements seen, percentage of EC, proliferation
index and relapse status 
Age Histology % MTU Proliferation index (%) Relapse 
19 TM, TI, EC 1 0 No 
33 TM, TI, YS 0 1 No 
35 TM, TI 0 3 No 
29 TI (with spindle cell components) 0 1 No 
36 TM, TI 0 72 No 
22 EC, N 5 1 No 
49 TM, TI, EC 1 4 No 
35 N, TM, EC 1 5 No 
53 EC 100 11 No 
47 N, TI 0 33 No 
21 TI 0 15 No 
28 N, EC 25 50 No 
25 TM, TI 0 44 No 
45 TI, TM, N 0 26 No 
22 N, EC 15 49 No 
34 TI: neural elements and TM (glia) 0 54 No 
51 EC 100 55 Yes 
33 CA (clear cell carcinoma) 100a 41 Yes 
28 EC, N, TM 5 75 Yes 
42 EC 100 24 Yes 
27 TI, TD 0 7 Yes 
24 TM, YS, EC 10 33 Yes 
26 EC, TI, N 50 28 Yes 
21 EC, YS, TI 75 60 Yes 
28 EC, TM, N 50 26 Yes 
33 EC 100 59 Yes 
24 EC 100 54 Yes 
43 EC, N 90 16 Yes 
aCarcinomatous transformation was counted as EC. EC = embryonal carcinoma; TI = teratoma, immature; 
TM = teratoma, mature; YC = yolk sac; N = necrosis; CA = carcinomatous transformation. 342 DM Berney et al 
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Relationship between patient outcome and initial risk of
relapse as assessed by the IGCCCG classification 
When patient outcome was revealed the IGCCCG classification
(International Germ Cell Cancer Collaborative Group, 1997)
which was available for 26/28 of the patients was noted. This clas-
sification ascribes risk of relapse to the degree of elevation of
tumour markers and the sites of metastatic disease. 33% (4/12) of
those in the good prognostic group relapsed compared to 70%
(7/10) in the intermediate group and 25% (1/4) in the poor group.
Thus, there was no correlation between prognostic group at
presentation and the risk of relapse in those with residual malig-
nant elements following surgery. 
DISCUSSION 
Effective salvage therapy exists for patients that relapse after a
retroperitoneal lymph node dissection of a malignant residual mass
(Loehrer et al, 1998; Shamash et al, 1999). Because of the rarity of
metastatic germ cell tumours there are few publications correlating
histology and recurrence rates in these tumours and to our knowl-
edge, none that examine the proliferation rate in residual post-
chemotherapy tumours. Immunohistochemical studies have been
performed in patients with clinical stage I disease and correlated
with later metastasis, but have not been investigated in the residual
masses (Eid et al, 1998). 
Richie and Kantoff (1991) had only 3/39 (8%) relapses in their
series, while Tait et al (1984) had a relapse rate of 9/16 (56%). In
the largest series (Stenning et al, 1998), 25% of all their patients
(including those with teratoma, differentiated or necrosis) experi-
enced disease progression and 60% of those with malignant
elements relapsed. Persistent malignant elements and incomplete
resection were independent risk factors. However 65% of patients
with residual malignancy had post-resection adjuvant chemo-
therapy and no attempt was made to quantify the proportion of the
different elements. Our series had 12/28 (42%) relapses. Patients
that remain progression free, have been followed up for a
minimum of 36 months. 
Unsurprisingly, many papers emphasize the importance of
complete resections of the masses (Fox et al, 1993; Fizazi et al,
1999; Albers et al, 2000). The malignant elements were all
completely resected in our series. However, it might have been
expected that patients who presented with nodal metastatic disease
only (Stage 2 or 3) would be more likely to be cured by surgery
than those who presented with distant non-nodal metastases. There
were 20 such patients of whom 9 relapsed (8 had greater than 25%
EC and 7 of these have relapsed). 8 patients had stage 4 disease at
presentation and 3 relapsed. One had greater than 25% EC.
Therefore the stage of the disease at presentation seems to play
little part in the likelihood of relapse. 
There appears to be no association between IGCCCG classifica-
tion and relapse. This may be because of the small numbers of the
group, but nevertheless suggests that histological parameters will
assess more accurately the need for salvage chemotherapy. 
The most significant finding of this study was that histopatho-
logical quantification of the proportion of residual EC is a statisti-
cally significant predictor of patient relapse (P < 0.0006). The
presence of EC and recently the proportion of EC within orchidec-
tomy specimens has been shown to be a significant risk factor for
occult retroperitoneal disease in patients with clinical stage I
disease (Heidenreich et al, 1998). In this study, 80% EC was found
to have a positive predictive value of 84% for presence of meta-
stases. Two studies, which looked at the EC component of retr-
operitoneal lymph nodes, produced conflicting results. Javadpour
and Young (1986) found that a predominance of EC was associ-
ated with an increased relapse rate after RPLND, whereas Richie
and Kantoff (1991) did not find a statistically significant associa-
tion. Most of these series however are biased by the fact that
chemotherapy was given to some of the patients after RPLND.
This in-built bias means that these authors cannot predict the
necessity for further chemotherapy after RPLND. Fizazi et al
(1999) have reported a multi-centre study examining ‘viable
malignant cells’ in RPLNDs in 140 patients, 29% of whom were
not given post-surgery chemotherapy. The percentage of malignant
cells was an important risk factor for relapse (P = 0.02). Our study
is the largest single-centre series to date of RPLNDs with residual
EC in which no further chemotherapy was not given until a clin-
ically proven relapse had occurred. If our results had been applied
clinically, using 25% EC as a cut-off point, we would have been
able to predict 15 of the 18 patients that did not relapse and only 1
out of 10 would have received unnecessary chemotherapy. These
figures alone make >25% EC appear as a good predictor of
relapse. It also has the advantage of being fairly simple to measure.
A higher proportion of the progression-free patients had TI present
(58.8% compared to 18.2%) but this failed to achieve statistical
significance (P < 0.0855). This may simply be a reflection of the
greater EC composition in the relapse group. No association was
seen between proportion of the mass that was necrotic and likeli-
hood of relapse. Aprikian et al (1994) and Herr (1997) found
necrosis seen at frozen section to be associated with a decreased
tendency to relapse, allowing a limited retroperitoneal
lymphadenectomy. In our experience, this is not the case, though
frozen sectioning of RPLNDs is not used in our centre and the
studies are therefore not easily comparable. Assessment of
RPLNDs for different malignant elements is extremely difficult
and this is recognized in the published literature (Stenning et al,
1998). It may be difficult to distinguish carcinomatous overgrowth
from EC and also to identify extremely small foci of malignancy
and to differentiate these areas from TI. This is one reason that in
this study it was thought that a measurement of the proliferation
index might provide more objective evidence for the likelihood of
recurrence than a histopathological opinion. 
The presence of ‘carcinomatous’ or ‘sarcomatous’ change
within RPLNDs has been occasionally reported. Little et al (1994)
found these changes in over 8% of their RPLNDs and Hines et al
(1997) reported 5 sarcomas out of 88 patients, but Stenning et al
(1998) none, despite searching specifically for them. In our series,
there was one case of clear cell carcinoma and another case with a
partially sarcomatous component which was a minority of the
tumour and therefore classified as TI. The case of clear cell carci-
noma was the only one of the patients that has recurred at greater
than 2 years from resection and is therefore a late recurrence.
Michael at al (2000) who examined a series of late recurrences of
germ cell tumours, emphasized their poor chemo-responsiveness
and suggested that when no teratoma was present, they be treated
with surgical excision, where possible. We therefore counted this
case for the purposes of analysis as EC, although they tend to be
refractory to treatment with germ cell chemotherapy regimens. 
Numerous reports exist on the utility of tumour proliferative
activity in solid cancers for predicting prognosis (Statin et al,
1997) and most studies show Ki-67 to have greater predictive
value than proliferating cell nuclear antigen (Leonardi et al, 1992).Predicting relapse in metastatic germ cell tumours 343
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However, the utility of tumour proliferative activity, for predicting
clinical stage I patients with metastases has produced conflicting
results. Albers et al (1995, 1997) found a significant difference to
exist between patients with and without metastases, whereas
Heidenreich and Moul (1997) and Fernandez et al (1994) found no
difference between the two groups. In this study a significantly
greater (P < 0.05) proliferation index was found in patients that
relapsed, but the positive predictive value (PPV) was only 71.4%
if a cut off of >75% was used. This compares with a PPV of 90%
in Albers et al (1997) on the primary tumours. The proliferation
index therefore provided significant data though appeared to be
less useful than histopathological assessment. 
In conclusion, proliferation rate and percentage of EC are both
useful indicators for the need for further chemotherapy in patients
with residual immature or undifferentiated elements in RPLNDs.
The percentage of EC alone appears to be the best predictor of
relapse though the proliferation index may help to identify cases
with a high relapse risk, which are difficult to classify using
routine techniques. These initial data may lead to a strategy to
prevent the unnecessary administration of chemotherapy to
patients who have undergone RPLND and whose mass contains a
malignant component. 
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